Monoclonal Patents (Class 530/864)
-
Patent number: 7446182Abstract: A composition and method for treating a host having or at risk of infection by Bacillus anthracis using an affinity matured antibody or portion thereof derived from a monoclonal antibody.Type: GrantFiled: November 5, 2002Date of Patent: November 4, 2008Assignee: Board of Regents, The University of Texas SystemInventors: George Georgiou, Brent L. Iverson, Jennifer A. Maynard
-
Patent number: 7410771Abstract: A reagent and method for the specific and highly sensitive detection of C. parvum in which the reagent is an antibody for a soluble C. parvum sporozoite antigen and the method is an immunoassay in which the antibody is used to detect or quantify C. parvum sporozoite antigen in a sample. The sample is treated to cause excystation of C. parvum oocytes, thereby releasing a C. parvum sporozoite antigen, and combined with antibodies specific for the sporozoite antigen under conditions to form an antibody-antigen complex. Detection of the complex indicates the presence of C. parvum in the sample. The assay allows recognition and detection of C. parvum in turbid samples, and due to a lack of crossreactivity with other Cryptosporidium species, is specific for C. parvum contamination or infection. The assay is highly sensitive, allowing for the detection of less than 100 oocysts per milliliter of sample.Type: GrantFiled: April 14, 2006Date of Patent: August 12, 2008Assignee: The United States of America as represented by the Department of Health and Human Services, Center for Disease Control and PreventionInventors: Victor C. W. Tsang, Jeffrey L. Call, Yeuk-mui Lee, Kathy Hancock
-
Patent number: 7276375Abstract: A novel monoclonal antibody that specifically recognizes phosphatidylinositol-3,4,5-triphosphate (PIP3) but does not cross-react with structurally similar phospholipid antigens is advantageous for PIP3-specific immunoassay. The gene in the variable regions of the monoclonal antibody has been identified, which enables producing recombinant antibodies.Type: GrantFiled: September 30, 2004Date of Patent: October 2, 2007Assignees: Medical & Biological Laboratories Co., Ltd.Inventors: Yasuhisa Fukui, Satoshi Nagata, Ryuichi Shirai
-
Patent number: 7056509Abstract: Disclosed are antibodies that specifically inhibit VEGF binding to only one (VEGFR2) of the two VEGF receptors. The antibodies effectively inhibit angiogenesis and induce tumor regression, and yet have improved safety due to their specificity. The present invention thus provides new antibody-based compositions, methods and combined protocols for treating cancer and other angiogenic diseases. Advantageous immunoconjugate and prodrug compositions and methods using the new VEGF-specific antibodies are also provided.Type: GrantFiled: February 24, 2003Date of Patent: June 6, 2006Assignee: Board of Regents The University of Texas SystemInventors: Philip E. Thorpe, Rolf A. Brekken
-
Patent number: 6531578Abstract: A panel of monoclonal antibodies recognizing and binding to human inducible nitric oxide synthase (iNOS or type II iNOS) enzyme have been developed. The monoclonal antibodies may also be employed in an assay to detect the presence and/or quantitate the amount of human iNOS.Type: GrantFiled: April 12, 1996Date of Patent: March 11, 2003Inventor: Robert Webber
-
Patent number: 6524583Abstract: Disclosed are antibodies that specifically inhibit VEGF binding to only one (VEGFR2) of the two VEGF receptors. The antibodies effectively inhibit angiogenesis and induce tumor regression, and yet have improved safety due to their specificity. The present invention thus provides new antibody-based compositions, methods and combined protocols for treating cancer and other angiogenic diseases. Advantageous immunoconjugate and prodrug compositions and methods using the new VEGF-specific antibodies are also provided.Type: GrantFiled: April 28, 2000Date of Patent: February 25, 2003Assignee: Board of Regents, The University of Texas SystemInventors: Philip E. Thorpe, Rolf A. Brekken
-
Patent number: 6423546Abstract: The present invention relates to novel monoclonal antibodies reactive with lipid transfer proteins typically found in foaming beverages. More specifically, the present invention relates to novel monoclonal antibodies raised against the native and denatured forms of barley lipid transfer protein 1, and an assay for determining the content of said proteins in foaming beverages at various stages of their production.Type: GrantFiled: November 2, 2000Date of Patent: July 23, 2002Assignee: Miller Brewing CompanyInventors: Lance T. Lusk, Alfonso L. Navarro, Henry Goldstein, Randall J. Wagner, David S. Ryder
-
Patent number: 6342219Abstract: Disclosed are antibodies that specifically inhibit VEGF binding to only one (VEGFR2) of the two VEGF receptors. The antibodies effectively inhibit angiogenesis and induce tumor regression, and yet have improved safety due to their specificity. The present invention thus provides new antibody-based compositions, methods and combined protocols for treating cancer and other angiogenic diseases. Advantageous immunoconjugate and prodrug compositions and methods using the new VEGF-specific antibodies are also provided.Type: GrantFiled: April 28, 2000Date of Patent: January 29, 2002Assignee: Board of Regents, The University of Texas SystemInventors: Philip E. Thorpe, Rolf A. Brekken
-
Patent number: 6333397Abstract: An immunoassay for the determination of myocardial necroses using antibodies to troponin T and a binding partner B for troponin T or for the an antibody, whereby either the antibody or the binding partner B is labelled with a determinable group. The immunological complex formed which contains the determinable group is isolated by separation of the phases and the determinable group is determined in one of the phases. Furthermore, monoclonal and polyclonal antibodies to troponin T are described with a cross-reactivity of less than 5% to skeletal muscle troponin T and less than 2% to troponin I and other myofibrillar proteins.Type: GrantFiled: February 17, 2000Date of Patent: December 25, 2001Assignee: Roche Diagnostics GmbHInventors: Hugo Katus, Anneliese Borgya, Klaus Hallermayer, Siegfried Looser
-
Patent number: 6133428Abstract: A substantially pure protein, Gab1, that binds to Grb2 is disclosed. Isolated nucleic acid molecules that encode Gab1 is disclosed. Pharmaceutical compositions comprising a pharmaceutically acceptable carrier in combination with nucleic acid molecules are disclosed. Fragments of nucleic acid molecules that encode Gab1 having at least 10 nucleotides and oligonucleotide molecule comprising a nucleotide sequence complimentary to a nucleotide sequence of at least 10 nucleotides are disclosed. Recombinant expression vectors that comprise the nucleic acid molecule that encode Gab1, and host cells that comprise such recombinant vectors are disclosed. Antibodies that bind to an epitope on Gab1 are disclosed. Methods of identifying inhibitors, activators and substrates of Gab1 are disclosed. Antisense compounds and methods of using the same are disclosed.Type: GrantFiled: August 21, 1998Date of Patent: October 17, 2000Assignee: Thomas Jefferson UniversityInventors: Albert J. Wong, Marina Holgado-Madruga
-
Patent number: 6124439Abstract: The present invention relates generally to the control of body weight of animals including mammals and humans, and more particularly to materials identified herein as modulators of body weight, and to diagnostic and therapeutic uses of such modulators. In its broadest aspect, the present invention relates to nucleotide sequences corresponding to the murine and human OB gene, and two isoforms thereof, and proteins expressed by such nucleotides or degenerate variations thereof, that demonstrate the ability to participate in the control of mammalian body weight and that have been postulated to play a critical role in the regulation of body weight and adiposity. The present invention further provides nucleic acid molecules for use as molecular probes or as primers for polymerase chain reaction (PCR) amplification. In further aspects, the present invention provides cloning vectors and mammalian expression vectors comprising the nucleic acid molecules of the invention.Type: GrantFiled: June 7, 1995Date of Patent: September 26, 2000Assignee: The Rockefeller UniversityInventors: Jeffrey M. Friedman, Yiying Zhang, Ricardo Proenca
-
Patent number: 5965378Abstract: The invention concerns a composition composed of several different antibodies or/and antibody fragments which is suitable as a reagent to reduce interferences in an immunological method for the class-specific detection of antibodies from one or several of the immunoglobulin classes G, M, A, D and E.Type: GrantFiled: April 24, 1997Date of Patent: October 12, 1999Assignee: Roche Diagnostics GmbHInventors: Dittmar Schlieper, Helmut Lenz, Urban Schmitt, Volker Klemt
-
Patent number: 5534255Abstract: This invention provides a monoclonal antibody or its fragment specific to a human .alpha..sub.2 -plasmin inhibitor, said antibody having the function of specifically blocking that site of the human .alpha..sub.2 -plasmin inhibitor which inhibits the fibrinolytic activity of plasmin, and of suppressing said fibrinolytic activity inhibiting function of said .alpha..sub.2 -plasmin inhibitor, and also a hybridoma capable of producing the monoclonal antibody. Said monoclonal antibody or its fragment is useful for the immunological determination of a human .alpha..sub.2 -plasmin inhibitor, the separation or recovery of a human .alpha..sub.2 -plasmin inhibitor from a liquid containing the human .alpha..sub.2 -plasmin inhibitor, and the treatment of a thrombotic disease.Type: GrantFiled: June 17, 1991Date of Patent: July 9, 1996Assignee: Teijin LimitedInventors: Yoshihiko Sumi, Yukiya Koike, Yataro Ichikawa, Nobuhiko Yoshida, Nobuo Aoki
-
Patent number: 5532137Abstract: Monoclonal or polyclonal antibodies capable of recognizing at least one antigenic determinant located on the FR-900506 compound, are disclosed. FR-900506 isa compound having pharmacological activities such as immunosuppressive activity and antimicrobial activity, and has the following structure: ##STR1## Also disclosed are enzyme immunoassays for FR-900506 based on the antibodies of the invention and test kits for detection of FR-900506. A process for preparing a monoclonal antibody which selectively binds to FR-900506 is also disclosed.Type: GrantFiled: June 6, 1996Date of Patent: July 2, 1996Assignee: Fujisawa Pharmaceutical Co., Ltd.Inventors: Mineo Niwa, Kouichi Tamura, Tsutomu Kaizu, Masakazu Kobayashi
-
Patent number: 5496802Abstract: A protein which inhibits milk secretion by lactating cows and which is present in the eighth (6B, Figure) significant peak when a nominally 10-30 KDa fraction of the whey proteins of the milk is resolved on a "Mono Q" anion exchange column using 10 mM imidazole buffer, pH 7.0 and a sodium chloride elution gradient.Type: GrantFiled: November 8, 1993Date of Patent: March 5, 1996Assignee: British Technology Group LtdInventors: Colin J. Wilde, Malcolm Peaker, Caroline V. P. Addey
-
Patent number: 5194592Abstract: Novel hG-CSF polypeptide derivatives having an amino acid sequence derived from the amino acid sequence of the human granulocyte colony stimulating factor polypeptide by substitution of at least one amino acid by a different aminoacid and/or deletion of at least one amino acid, recombinant plasmids containing a DNA fragment insert coding for any of these hG-CSF polypeptide derivatives, microorganisms carrying one of such plasmids, and methods of producing the hG-CSF polypeptide derivatives using the microorganisms are described.Type: GrantFiled: March 3, 1989Date of Patent: March 16, 1993Assignee: Kyowa Hakko Kogyo Co. Ltd.Inventor: Hajime Yoshida
-
Patent number: 5171666Abstract: The present invention relates to a novel tumor-associated antigen that is a cell-surface glycoprotein having a molecular weight in the range of 110,000-140,000 daltons that is present in a variety of carcinomas, including squamous cell carcinomas and adenocarcinomas. The invention also comprises antibodies reactive with the antigen, hybridoma cell lines that produce the antibodies of the invention, and methods for using the antibodies in the diagnosis and treatment of cancer.Type: GrantFiled: October 19, 1988Date of Patent: December 15, 1992Assignee: Eli Lilly and CompanyInventors: Magda C. Gutowski, David A. Johnson
-
Patent number: 5169774Abstract: Murine monoclonal antibodies, or fragments thereof, that bind selectively to human breast cancer cells, are IgGs or IgMs, and when conjugated to ricin A chain, exhibit a TCID 50% against at least one of MCF-7, CAMA-1, SKBR-3, or BT-20 cells of less than about 10 nM. Methods for diagnosing, monitoring, and treating human breast cancer with the antibodies or immunotoxins made therefrom are described.Type: GrantFiled: May 6, 1988Date of Patent: December 8, 1992Assignee: Cetus Oncology CorporationInventors: Arthur E. Frankel, David B. Ring, Walter Laird
-
Patent number: 5166050Abstract: Methods and composition for HIV diagnosis and treatment using monoclonal antibodies reactive with one or more neutralizing regions of HIV proteins, using the peptides or homologs thereof from that region, and using related nucleic acid segments. Exemplary neutralizing regions include selected portions of the env and gag genes from various HIV isolates. Monoclonal antibody secreting cell lines include HIV-gp110-1, -2, -3, -4, -5 and -6 (A.T.C.C. Accession Nos. HB9175, HB9176, HB9177, HV9405, HB9406 and HB9404, respectively) and HIV-p25-2, -3, -6 and -7 (A.T.C.C. Accession Nos. HB9407, HB9408, HB9409 and HB9410, respectively).Type: GrantFiled: December 7, 1990Date of Patent: November 24, 1992Assignee: Bristol-Myers Squibb CompanyInventors: Mary K. Shriver, Larry H. Gosting, Edna S. Dickinson, Janela McClure, Elaine K. Thomas, Wesley L. Cosand
-
Patent number: 5157113Abstract: An essentially pure and stablized antibody preparation comprising IgM antibodies having a purity greater than about 98% by weight and a nucleic acid content of less than about 200 pg per mg IgM. In one embodiment IgM antibodies from a monoclonal source are subjected to ion exchange and size exclusion chromatography at an alkaline pH to yield a purified IgM having a nucleic acid content of less than 10 pg/mg IgM, preferably less than about 4 pg/mg IgM. A highly purified and stabilized preparation of anti Pseudomonas aeruginosa antibodies is disclosed. The removal of nucleic acids is assured by subjecting the antibody source to at least one and preferably two low pH precipitation steps. In a very preferred embodiment, ion exchange and/or size exclusion chromatography is used to remove any residual nucleic acids.Type: GrantFiled: April 12, 1991Date of Patent: October 20, 1992Assignee: Miles Inc.Inventors: George Dove, Gautam Mitra
-
Patent number: 5141864Abstract: A hybridoma capable of producing a monoclonal antibody specific to a sialic acid containing glycolipid carrying N-acetylneuraminic acid residue having alpha 2.fwdarw.3 linkage is herein disclosed. The hybridoma can be generated by fusing (i) B cells or lymphocytes obtained by immunizing an animal with a sialic acid containing glycolipid carrying N-acetylneuraminic acid residue having alpha 2.fwdarw.3 linkage and (ii) myeloma cells. The monoclonal antibody produced by the hybridoma can be used for purifying gangliosides, for treating patients suffering from melanoma and for diagnosing sera.Type: GrantFiled: November 14, 1988Date of Patent: August 25, 1992Assignee: Mect CorporationInventors: Yoshitaka Nagai, Hideki Yamamoto, Kinji Takada, Ito, Yoshiyasu Shitori
-
Patent number: 5112952Abstract: Preparation of a composite of mannan binding protein attached to an insoluble, support matrix is accomplished by reacting cyanogen bromide activated beaded agarose with a buffered solution of mannan binding protein isolated from rabbit serum. The composite has utility as an affinity sorbent for IgM when divalent metal ions are incorporated in the binding buffer. The composite does not show cross-reactivity (binding) with immunoglobulins of the G class.Type: GrantFiled: September 28, 1990Date of Patent: May 12, 1992Assignee: Pierce Chemical CompanyInventors: A. Krishna Mallia, Marten W. Wendt